nodes	percent_of_prediction	percent_of_DWPC	metapath
Zafirlukast—CYP3A4—bone cancer	0.532	1	CbGaD
Zafirlukast—ABCG2—Carboplatin—bone cancer	0.0898	0.276	CbGbCtD
Zafirlukast—ABCG2—Cisplatin—bone cancer	0.0767	0.236	CbGbCtD
Zafirlukast—ABCG2—Doxorubicin—bone cancer	0.0514	0.158	CbGbCtD
Zafirlukast—ABCG2—Methotrexate—bone cancer	0.0498	0.153	CbGbCtD
Zafirlukast—CYP2C9—Cisplatin—bone cancer	0.0285	0.0877	CbGbCtD
Zafirlukast—CYP2D6—Doxorubicin—bone cancer	0.0175	0.0538	CbGbCtD
Zafirlukast—CYP3A4—Doxorubicin—bone cancer	0.0111	0.0342	CbGbCtD
Zafirlukast—Tolvaptan—CYP3A4—bone cancer	0.00253	0.768	CrCbGaD
Zafirlukast—Hepatotoxicity—Cisplatin—bone cancer	0.00125	0.0239	CcSEcCtD
Zafirlukast—Infection—Carboplatin—bone cancer	0.00116	0.0223	CcSEcCtD
Zafirlukast—Raised liver function tests—Methotrexate—bone cancer	0.00114	0.022	CcSEcCtD
Zafirlukast—Liver injury—Cisplatin—bone cancer	0.00114	0.022	CcSEcCtD
Zafirlukast—Leukocytoclastic vasculitis—Methotrexate—bone cancer	0.00108	0.0207	CcSEcCtD
Zafirlukast—Pain—Carboplatin—bone cancer	0.001	0.0192	CcSEcCtD
Zafirlukast—Body temperature increased—Carboplatin—bone cancer	0.000926	0.0178	CcSEcCtD
Zafirlukast—Neuropathy—Cisplatin—bone cancer	0.000904	0.0174	CcSEcCtD
Zafirlukast—Glyburide—CYP3A4—bone cancer	0.000762	0.232	CrCbGaD
Zafirlukast—Haematemesis—Methotrexate—bone cancer	0.000761	0.0146	CcSEcCtD
Zafirlukast—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000755	0.00866	CbGpPWpGaD
Zafirlukast—CYSLTR2—GPCR ligand binding—GRM4—bone cancer	0.000751	0.00862	CbGpPWpGaD
Zafirlukast—CYSLTR2—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000745	0.00854	CbGpPWpGaD
Zafirlukast—CYSLTR2—Endothelins—JUN—bone cancer	0.00072	0.00826	CbGpPWpGaD
Zafirlukast—Haematemesis—Epirubicin—bone cancer	0.000712	0.0137	CcSEcCtD
Zafirlukast—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000711	0.00815	CbGpPWpGaD
Zafirlukast—CYP2E1—Metapathway biotransformation—CYP4V2—bone cancer	0.000701	0.00804	CbGpPWpGaD
Zafirlukast—Blister—Epirubicin—bone cancer	0.000686	0.0132	CcSEcCtD
Zafirlukast—Hepatotoxicity—Methotrexate—bone cancer	0.000685	0.0131	CcSEcCtD
Zafirlukast—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.000679	0.00779	CbGpPWpGaD
Zafirlukast—Haemoptysis—Epirubicin—bone cancer	0.000668	0.0128	CcSEcCtD
Zafirlukast—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000666	0.00765	CbGpPWpGaD
Zafirlukast—Haematemesis—Doxorubicin—bone cancer	0.000659	0.0126	CcSEcCtD
Zafirlukast—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.000653	0.00749	CbGpPWpGaD
Zafirlukast—CYSLTR2—GPCR ligand binding—GRM1—bone cancer	0.000652	0.00747	CbGpPWpGaD
Zafirlukast—Blister—Doxorubicin—bone cancer	0.000635	0.0122	CcSEcCtD
Zafirlukast—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—bone cancer	0.00062	0.00711	CbGpPWpGaD
Zafirlukast—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000619	0.0071	CbGpPWpGaD
Zafirlukast—Haemoptysis—Doxorubicin—bone cancer	0.000618	0.0119	CcSEcCtD
Zafirlukast—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000606	0.00695	CbGpPWpGaD
Zafirlukast—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.000606	0.00695	CbGpPWpGaD
Zafirlukast—Blood disorder—Epirubicin—bone cancer	0.000592	0.0114	CcSEcCtD
Zafirlukast—Liver injury—Epirubicin—bone cancer	0.000588	0.0113	CcSEcCtD
Zafirlukast—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000583	0.00669	CbGpPWpGaD
Zafirlukast—Hyperbilirubinaemia—Methotrexate—bone cancer	0.000581	0.0112	CcSEcCtD
Zafirlukast—Abdominal discomfort—Cisplatin—bone cancer	0.000579	0.0111	CcSEcCtD
Zafirlukast—CYSLTR1—G alpha (q) signalling events—GNA11—bone cancer	0.000577	0.00662	CbGpPWpGaD
Zafirlukast—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000565	0.00648	CbGpPWpGaD
Zafirlukast—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000557	0.0064	CbGpPWpGaD
Zafirlukast—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000553	0.00634	CbGpPWpGaD
Zafirlukast—Blood disorder—Doxorubicin—bone cancer	0.000548	0.0105	CcSEcCtD
Zafirlukast—Rectal haemorrhage—Epirubicin—bone cancer	0.000548	0.0105	CcSEcCtD
Zafirlukast—Hyperbilirubinaemia—Epirubicin—bone cancer	0.000544	0.0104	CcSEcCtD
Zafirlukast—Liver injury—Doxorubicin—bone cancer	0.000544	0.0104	CcSEcCtD
Zafirlukast—Vasculitis—Methotrexate—bone cancer	0.000542	0.0104	CcSEcCtD
Zafirlukast—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000541	0.0062	CbGpPWpGaD
Zafirlukast—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000536	0.00615	CbGpPWpGaD
Zafirlukast—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000532	0.0061	CbGpPWpGaD
Zafirlukast—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000529	0.00607	CbGpPWpGaD
Zafirlukast—Neuropathy peripheral—Cisplatin—bone cancer	0.000528	0.0101	CcSEcCtD
Zafirlukast—CYSLTR1—GPCR ligand binding—GRM4—bone cancer	0.000521	0.00598	CbGpPWpGaD
Zafirlukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000516	0.00592	CbGpPWpGaD
Zafirlukast—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000514	0.0059	CbGpPWpGaD
Zafirlukast—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000514	0.00589	CbGpPWpGaD
Zafirlukast—Rectal haemorrhage—Doxorubicin—bone cancer	0.000507	0.00973	CcSEcCtD
Zafirlukast—Hyperbilirubinaemia—Doxorubicin—bone cancer	0.000503	0.00966	CcSEcCtD
Zafirlukast—CYSLTR1—Endothelins—JUN—bone cancer	0.000499	0.00573	CbGpPWpGaD
Zafirlukast—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000497	0.0057	CbGpPWpGaD
Zafirlukast—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000493	0.00565	CbGpPWpGaD
Zafirlukast—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000492	0.00564	CbGpPWpGaD
Zafirlukast—PTGS1—Overview of nanoparticle effects—PTGS2—bone cancer	0.000485	0.00557	CbGpPWpGaD
Zafirlukast—Influenza like illness—Epirubicin—bone cancer	0.00048	0.00922	CcSEcCtD
Zafirlukast—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000472	0.00542	CbGpPWpGaD
Zafirlukast—Neuropathy—Epirubicin—bone cancer	0.000464	0.00891	CcSEcCtD
Zafirlukast—CYSLTR2—GPCR ligand binding—SMO—bone cancer	0.000459	0.00527	CbGpPWpGaD
Zafirlukast—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000454	0.00521	CbGpPWpGaD
Zafirlukast—CYSLTR1—GPCR ligand binding—GRM1—bone cancer	0.000452	0.00518	CbGpPWpGaD
Zafirlukast—Influenza like illness—Doxorubicin—bone cancer	0.000445	0.00853	CcSEcCtD
Zafirlukast—Neuropathy—Doxorubicin—bone cancer	0.00043	0.00825	CcSEcCtD
Zafirlukast—Hepatic failure—Methotrexate—bone cancer	0.000427	0.00819	CcSEcCtD
Zafirlukast—CYSLTR2—GPCR downstream signaling—GRM4—bone cancer	0.000425	0.00487	CbGpPWpGaD
Zafirlukast—CYSLTR2—GPCR downstream signaling—RGS1—bone cancer	0.000425	0.00487	CbGpPWpGaD
Zafirlukast—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000421	0.00483	CbGpPWpGaD
Zafirlukast—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000416	0.00477	CbGpPWpGaD
Zafirlukast—Hepatic function abnormal—Epirubicin—bone cancer	0.000411	0.00789	CcSEcCtD
Zafirlukast—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000408	0.00468	CbGpPWpGaD
Zafirlukast—CYP2E1—Tryptophan metabolism—CYP3A4—bone cancer	0.000403	0.00463	CbGpPWpGaD
Zafirlukast—PTGS1—Eicosanoid Synthesis—PTGS2—bone cancer	0.000403	0.00462	CbGpPWpGaD
Zafirlukast—Hepatic failure—Epirubicin—bone cancer	0.0004	0.00767	CcSEcCtD
Zafirlukast—Ill-defined disorder—Cisplatin—bone cancer	0.000391	0.0075	CcSEcCtD
Zafirlukast—CYSLTR2—Signaling by GPCR—GRM4—bone cancer	0.000386	0.00442	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling by GPCR—RGS1—bone cancer	0.000386	0.00442	CbGpPWpGaD
Zafirlukast—Hepatic function abnormal—Doxorubicin—bone cancer	0.00038	0.0073	CcSEcCtD
Zafirlukast—Malaise—Cisplatin—bone cancer	0.00038	0.00729	CcSEcCtD
Zafirlukast—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000379	0.00435	CbGpPWpGaD
Zafirlukast—Dermatitis bullous—Epirubicin—bone cancer	0.000376	0.00721	CcSEcCtD
Zafirlukast—Hepatic failure—Doxorubicin—bone cancer	0.00037	0.0071	CcSEcCtD
Zafirlukast—CYSLTR2—GPCR downstream signaling—GRM1—bone cancer	0.000368	0.00422	CbGpPWpGaD
Zafirlukast—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000361	0.00415	CbGpPWpGaD
Zafirlukast—Myalgia—Cisplatin—bone cancer	0.000359	0.00688	CcSEcCtD
Zafirlukast—Liver function test abnormal—Methotrexate—bone cancer	0.000354	0.0068	CcSEcCtD
Zafirlukast—Discomfort—Cisplatin—bone cancer	0.000354	0.0068	CcSEcCtD
Zafirlukast—PTGS1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000354	0.00406	CbGpPWpGaD
Zafirlukast—Dermatitis bullous—Doxorubicin—bone cancer	0.000348	0.00667	CcSEcCtD
Zafirlukast—Oedema—Cisplatin—bone cancer	0.000344	0.0066	CcSEcCtD
Zafirlukast—Infection—Cisplatin—bone cancer	0.000341	0.00655	CcSEcCtD
Zafirlukast—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.000337	0.00386	CbGpPWpGaD
Zafirlukast—Thrombocytopenia—Cisplatin—bone cancer	0.000336	0.00646	CcSEcCtD
Zafirlukast—CYSLTR2—Signaling by GPCR—GRM1—bone cancer	0.000334	0.00384	CbGpPWpGaD
Zafirlukast—Liver function test abnormal—Epirubicin—bone cancer	0.000332	0.00636	CcSEcCtD
Zafirlukast—Eosinophilia—Methotrexate—bone cancer	0.000328	0.0063	CcSEcCtD
Zafirlukast—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000326	0.00374	CbGpPWpGaD
Zafirlukast—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000325	0.00373	CbGpPWpGaD
Zafirlukast—CYP2E1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000322	0.00369	CbGpPWpGaD
Zafirlukast—CYSLTR1—GPCR ligand binding—SMO—bone cancer	0.000318	0.00365	CbGpPWpGaD
Zafirlukast—Abdominal discomfort—Methotrexate—bone cancer	0.000318	0.0061	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000313	0.00601	CcSEcCtD
Zafirlukast—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000312	0.00358	CbGpPWpGaD
Zafirlukast—Neutropenia—Methotrexate—bone cancer	0.00031	0.00595	CcSEcCtD
Zafirlukast—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000309	0.00354	CbGpPWpGaD
Zafirlukast—Eosinophilia—Epirubicin—bone cancer	0.000307	0.0059	CcSEcCtD
Zafirlukast—Liver function test abnormal—Doxorubicin—bone cancer	0.000307	0.00589	CcSEcCtD
Zafirlukast—Gastrointestinal disorder—Cisplatin—bone cancer	0.000297	0.00569	CcSEcCtD
Zafirlukast—CYSLTR1—GPCR downstream signaling—RGS1—bone cancer	0.000294	0.00338	CbGpPWpGaD
Zafirlukast—CYSLTR1—GPCR downstream signaling—GRM4—bone cancer	0.000294	0.00338	CbGpPWpGaD
Zafirlukast—Pain—Cisplatin—bone cancer	0.000294	0.00564	CcSEcCtD
Zafirlukast—Neutropenia—Epirubicin—bone cancer	0.00029	0.00557	CcSEcCtD
Zafirlukast—Eosinophilia—Doxorubicin—bone cancer	0.000284	0.00546	CcSEcCtD
Zafirlukast—Feeling abnormal—Cisplatin—bone cancer	0.000283	0.00544	CcSEcCtD
Zafirlukast—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000282	0.00323	CbGpPWpGaD
Zafirlukast—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000278	0.00319	CbGpPWpGaD
Zafirlukast—Agranulocytosis—Methotrexate—bone cancer	0.000276	0.0053	CcSEcCtD
Zafirlukast—Body temperature increased—Cisplatin—bone cancer	0.000272	0.00521	CcSEcCtD
Zafirlukast—Neuropathy peripheral—Epirubicin—bone cancer	0.000271	0.00521	CcSEcCtD
Zafirlukast—Jaundice—Epirubicin—bone cancer	0.00027	0.00518	CcSEcCtD
Zafirlukast—Neutropenia—Doxorubicin—bone cancer	0.000269	0.00515	CcSEcCtD
Zafirlukast—CYSLTR1—Signaling by GPCR—GRM4—bone cancer	0.000267	0.00307	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling by GPCR—RGS1—bone cancer	0.000267	0.00307	CbGpPWpGaD
Zafirlukast—Haemoglobin—Methotrexate—bone cancer	0.000267	0.00512	CcSEcCtD
Zafirlukast—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000266	0.00306	CbGpPWpGaD
Zafirlukast—Hepatitis—Methotrexate—bone cancer	0.000265	0.00509	CcSEcCtD
Zafirlukast—Haemorrhage—Methotrexate—bone cancer	0.000265	0.00509	CcSEcCtD
Zafirlukast—CYP2E1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000264	0.00303	CbGpPWpGaD
Zafirlukast—Sinusitis—Epirubicin—bone cancer	0.00026	0.00498	CcSEcCtD
Zafirlukast—Agranulocytosis—Epirubicin—bone cancer	0.000258	0.00496	CcSEcCtD
Zafirlukast—CYSLTR1—GPCR downstream signaling—GRM1—bone cancer	0.000255	0.00293	CbGpPWpGaD
Zafirlukast—Hypersensitivity—Cisplatin—bone cancer	0.000253	0.00486	CcSEcCtD
Zafirlukast—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000252	0.00289	CbGpPWpGaD
Zafirlukast—Neuropathy peripheral—Doxorubicin—bone cancer	0.000251	0.00482	CcSEcCtD
Zafirlukast—Haemoglobin—Epirubicin—bone cancer	0.00025	0.00479	CcSEcCtD
Zafirlukast—Jaundice—Doxorubicin—bone cancer	0.00025	0.00479	CcSEcCtD
Zafirlukast—Hepatitis—Epirubicin—bone cancer	0.000248	0.00477	CcSEcCtD
Zafirlukast—Haemorrhage—Epirubicin—bone cancer	0.000248	0.00477	CcSEcCtD
Zafirlukast—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000248	0.00285	CbGpPWpGaD
Zafirlukast—Hypoaesthesia—Epirubicin—bone cancer	0.000247	0.00474	CcSEcCtD
Zafirlukast—Asthenia—Cisplatin—bone cancer	0.000247	0.00473	CcSEcCtD
Zafirlukast—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000243	0.00278	CbGpPWpGaD
Zafirlukast—Sinusitis—Doxorubicin—bone cancer	0.00024	0.00461	CcSEcCtD
Zafirlukast—Agranulocytosis—Doxorubicin—bone cancer	0.000239	0.00459	CcSEcCtD
Zafirlukast—CYSLTR2—GPCR downstream signaling—GNA11—bone cancer	0.000237	0.00272	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling by GPCR—SMO—bone cancer	0.000236	0.0027	CbGpPWpGaD
Zafirlukast—Diarrhoea—Cisplatin—bone cancer	0.000235	0.00451	CcSEcCtD
Zafirlukast—CYSLTR1—Signaling by GPCR—GRM1—bone cancer	0.000232	0.00266	CbGpPWpGaD
Zafirlukast—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000231	0.00266	CbGpPWpGaD
Zafirlukast—Haemoglobin—Doxorubicin—bone cancer	0.000231	0.00443	CcSEcCtD
Zafirlukast—Hepatitis—Doxorubicin—bone cancer	0.00023	0.00441	CcSEcCtD
Zafirlukast—Haemorrhage—Doxorubicin—bone cancer	0.00023	0.00441	CcSEcCtD
Zafirlukast—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000229	0.00263	CbGpPWpGaD
Zafirlukast—Hypoaesthesia—Doxorubicin—bone cancer	0.000229	0.00439	CcSEcCtD
Zafirlukast—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000229	0.00262	CbGpPWpGaD
Zafirlukast—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000228	0.00262	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—RGS1—bone cancer	0.000228	0.00261	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—GRM4—bone cancer	0.000228	0.00261	CbGpPWpGaD
Zafirlukast—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000226	0.0026	CbGpPWpGaD
Zafirlukast—PTGS1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000224	0.00257	CbGpPWpGaD
Zafirlukast—Back pain—Methotrexate—bone cancer	0.000224	0.00429	CcSEcCtD
Zafirlukast—Vomiting—Cisplatin—bone cancer	0.000219	0.00419	CcSEcCtD
Zafirlukast—Rash—Cisplatin—bone cancer	0.000217	0.00416	CcSEcCtD
Zafirlukast—Dermatitis—Cisplatin—bone cancer	0.000216	0.00416	CcSEcCtD
Zafirlukast—CYSLTR2—Signaling by GPCR—GNA11—bone cancer	0.000215	0.00247	CbGpPWpGaD
Zafirlukast—CYSLTR2—GPCR downstream signaling—IL3—bone cancer	0.000215	0.00247	CbGpPWpGaD
Zafirlukast—Ill-defined disorder—Methotrexate—bone cancer	0.000214	0.00411	CcSEcCtD
Zafirlukast—CYSLTR2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000212	0.00243	CbGpPWpGaD
Zafirlukast—Back pain—Epirubicin—bone cancer	0.000209	0.00401	CcSEcCtD
Zafirlukast—Malaise—Methotrexate—bone cancer	0.000208	0.004	CcSEcCtD
Zafirlukast—Nausea—Cisplatin—bone cancer	0.000204	0.00392	CcSEcCtD
Zafirlukast—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000204	0.00234	CbGpPWpGaD
Zafirlukast—Ill-defined disorder—Epirubicin—bone cancer	0.000201	0.00385	CcSEcCtD
Zafirlukast—CYSLTR2—Signaling Pathways—GRM1—bone cancer	0.000198	0.00227	CbGpPWpGaD
Zafirlukast—Arthralgia—Methotrexate—bone cancer	0.000197	0.00378	CcSEcCtD
Zafirlukast—Myalgia—Methotrexate—bone cancer	0.000197	0.00378	CcSEcCtD
Zafirlukast—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000196	0.00225	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling by GPCR—IL3—bone cancer	0.000195	0.00224	CbGpPWpGaD
Zafirlukast—Malaise—Epirubicin—bone cancer	0.000195	0.00374	CcSEcCtD
Zafirlukast—Discomfort—Methotrexate—bone cancer	0.000194	0.00373	CcSEcCtD
Zafirlukast—Back pain—Doxorubicin—bone cancer	0.000194	0.00371	CcSEcCtD
Zafirlukast—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000194	0.00222	CbGpPWpGaD
Zafirlukast—ABCG2—Fluoropyrimidine Activity—TP53—bone cancer	0.000193	0.00222	CbGpPWpGaD
Zafirlukast—PTGS1—Biological oxidations—CYP3A4—bone cancer	0.000188	0.00216	CbGpPWpGaD
Zafirlukast—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000188	0.00215	CbGpPWpGaD
Zafirlukast—Infection—Methotrexate—bone cancer	0.000187	0.0036	CcSEcCtD
Zafirlukast—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000186	0.00213	CbGpPWpGaD
Zafirlukast—Ill-defined disorder—Doxorubicin—bone cancer	0.000186	0.00356	CcSEcCtD
Zafirlukast—CYP2E1—Tryptophan metabolism—MDM2—bone cancer	0.000185	0.00213	CbGpPWpGaD
Zafirlukast—Thrombocytopenia—Methotrexate—bone cancer	0.000185	0.00354	CcSEcCtD
Zafirlukast—Myalgia—Epirubicin—bone cancer	0.000184	0.00353	CcSEcCtD
Zafirlukast—Arthralgia—Epirubicin—bone cancer	0.000184	0.00353	CcSEcCtD
Zafirlukast—Discomfort—Epirubicin—bone cancer	0.000182	0.00349	CcSEcCtD
Zafirlukast—Malaise—Doxorubicin—bone cancer	0.00018	0.00346	CcSEcCtD
Zafirlukast—Oedema—Epirubicin—bone cancer	0.000176	0.00339	CcSEcCtD
Zafirlukast—Infection—Epirubicin—bone cancer	0.000175	0.00337	CcSEcCtD
Zafirlukast—Thrombocytopenia—Epirubicin—bone cancer	0.000173	0.00332	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000172	0.0033	CcSEcCtD
Zafirlukast—Insomnia—Methotrexate—bone cancer	0.000171	0.00327	CcSEcCtD
Zafirlukast—Arthralgia—Doxorubicin—bone cancer	0.00017	0.00327	CcSEcCtD
Zafirlukast—Myalgia—Doxorubicin—bone cancer	0.00017	0.00327	CcSEcCtD
Zafirlukast—Discomfort—Doxorubicin—bone cancer	0.000168	0.00323	CcSEcCtD
Zafirlukast—ABCG2—HIF-1-alpha transcription factor network—JUN—bone cancer	0.000168	0.00193	CbGpPWpGaD
Zafirlukast—Dyspepsia—Methotrexate—bone cancer	0.000166	0.00319	CcSEcCtD
Zafirlukast—CYSLTR1—GPCR downstream signaling—GNA11—bone cancer	0.000164	0.00189	CbGpPWpGaD
Zafirlukast—Oedema—Doxorubicin—bone cancer	0.000163	0.00313	CcSEcCtD
Zafirlukast—CYSLTR1—Signaling by GPCR—SMO—bone cancer	0.000163	0.00187	CbGpPWpGaD
Zafirlukast—Gastrointestinal disorder—Methotrexate—bone cancer	0.000163	0.00312	CcSEcCtD
Zafirlukast—Fatigue—Methotrexate—bone cancer	0.000163	0.00312	CcSEcCtD
Zafirlukast—Infection—Doxorubicin—bone cancer	0.000162	0.00311	CcSEcCtD
Zafirlukast—Pain—Methotrexate—bone cancer	0.000161	0.0031	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000161	0.00309	CcSEcCtD
Zafirlukast—PTGS1—Biological oxidations—GSTP1—bone cancer	0.000161	0.00184	CbGpPWpGaD
Zafirlukast—Thrombocytopenia—Doxorubicin—bone cancer	0.00016	0.00307	CcSEcCtD
Zafirlukast—Insomnia—Epirubicin—bone cancer	0.00016	0.00306	CcSEcCtD
Zafirlukast—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000159	0.00182	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—RGS1—bone cancer	0.000158	0.00181	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—GRM4—bone cancer	0.000158	0.00181	CbGpPWpGaD
Zafirlukast—Feeling abnormal—Methotrexate—bone cancer	0.000155	0.00298	CcSEcCtD
Zafirlukast—Dyspepsia—Epirubicin—bone cancer	0.000155	0.00298	CcSEcCtD
Zafirlukast—Gastrointestinal pain—Methotrexate—bone cancer	0.000154	0.00296	CcSEcCtD
Zafirlukast—Gastrointestinal disorder—Epirubicin—bone cancer	0.000152	0.00292	CcSEcCtD
Zafirlukast—Fatigue—Epirubicin—bone cancer	0.000152	0.00292	CcSEcCtD
Zafirlukast—Pain—Epirubicin—bone cancer	0.000151	0.0029	CcSEcCtD
Zafirlukast—ABCG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00015	0.00172	CbGpPWpGaD
Zafirlukast—Urticaria—Methotrexate—bone cancer	0.00015	0.00288	CcSEcCtD
Zafirlukast—CYSLTR1—Signaling by GPCR—GNA11—bone cancer	0.000149	0.00171	CbGpPWpGaD
Zafirlukast—CYSLTR1—GPCR downstream signaling—IL3—bone cancer	0.000149	0.00171	CbGpPWpGaD
Zafirlukast—Abdominal pain—Methotrexate—bone cancer	0.000149	0.00286	CcSEcCtD
Zafirlukast—Body temperature increased—Methotrexate—bone cancer	0.000149	0.00286	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000149	0.00286	CcSEcCtD
Zafirlukast—Insomnia—Doxorubicin—bone cancer	0.000148	0.00283	CcSEcCtD
Zafirlukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000147	0.00169	CbGpPWpGaD
Zafirlukast—Feeling abnormal—Epirubicin—bone cancer	0.000145	0.00279	CcSEcCtD
Zafirlukast—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	0.000145	0.00166	CbGpPWpGaD
Zafirlukast—Gastrointestinal pain—Epirubicin—bone cancer	0.000144	0.00277	CcSEcCtD
Zafirlukast—Dyspepsia—Doxorubicin—bone cancer	0.000144	0.00276	CcSEcCtD
Zafirlukast—PTGS1—Selenium Micronutrient Network—PTGS2—bone cancer	0.000142	0.00163	CbGpPWpGaD
Zafirlukast—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000141	0.00271	CcSEcCtD
Zafirlukast—Fatigue—Doxorubicin—bone cancer	0.000141	0.0027	CcSEcCtD
Zafirlukast—CYP2E1—Biological oxidations—CYP3A4—bone cancer	0.00014	0.00161	CbGpPWpGaD
Zafirlukast—Urticaria—Epirubicin—bone cancer	0.00014	0.00269	CcSEcCtD
Zafirlukast—Pain—Doxorubicin—bone cancer	0.00014	0.00268	CcSEcCtD
Zafirlukast—Abdominal pain—Epirubicin—bone cancer	0.00014	0.00268	CcSEcCtD
Zafirlukast—Body temperature increased—Epirubicin—bone cancer	0.00014	0.00268	CcSEcCtD
Zafirlukast—CYSLTR2—Signaling Pathways—SMO—bone cancer	0.000139	0.0016	CbGpPWpGaD
Zafirlukast—Hypersensitivity—Methotrexate—bone cancer	0.000139	0.00267	CcSEcCtD
Zafirlukast—CYP2E1—Metapathway biotransformation—CYP3A4—bone cancer	0.000139	0.00159	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—GRM1—bone cancer	0.000137	0.00157	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling by GPCR—IL3—bone cancer	0.000135	0.00155	CbGpPWpGaD
Zafirlukast—Asthenia—Methotrexate—bone cancer	0.000135	0.0026	CcSEcCtD
Zafirlukast—Feeling abnormal—Doxorubicin—bone cancer	0.000135	0.00258	CcSEcCtD
Zafirlukast—Gastrointestinal pain—Doxorubicin—bone cancer	0.000134	0.00256	CcSEcCtD
Zafirlukast—Pruritus—Methotrexate—bone cancer	0.000133	0.00256	CcSEcCtD
Zafirlukast—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000131	0.0015	CbGpPWpGaD
Zafirlukast—Hypersensitivity—Epirubicin—bone cancer	0.00013	0.0025	CcSEcCtD
Zafirlukast—Urticaria—Doxorubicin—bone cancer	0.00013	0.00249	CcSEcCtD
Zafirlukast—ABCG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000129	0.00149	CbGpPWpGaD
Zafirlukast—Body temperature increased—Doxorubicin—bone cancer	0.000129	0.00248	CcSEcCtD
Zafirlukast—Abdominal pain—Doxorubicin—bone cancer	0.000129	0.00248	CcSEcCtD
Zafirlukast—Diarrhoea—Methotrexate—bone cancer	0.000129	0.00248	CcSEcCtD
Zafirlukast—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000129	0.00148	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—GNA11—bone cancer	0.000127	0.00146	CbGpPWpGaD
Zafirlukast—Asthenia—Epirubicin—bone cancer	0.000127	0.00243	CcSEcCtD
Zafirlukast—Pruritus—Epirubicin—bone cancer	0.000125	0.0024	CcSEcCtD
Zafirlukast—Dizziness—Methotrexate—bone cancer	0.000125	0.00239	CcSEcCtD
Zafirlukast—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000123	0.00142	CbGpPWpGaD
Zafirlukast—CYP2C8—Biological oxidations—CYP3A4—bone cancer	0.000121	0.00139	CbGpPWpGaD
Zafirlukast—Diarrhoea—Epirubicin—bone cancer	0.000121	0.00232	CcSEcCtD
Zafirlukast—Hypersensitivity—Doxorubicin—bone cancer	0.00012	0.00231	CcSEcCtD
Zafirlukast—CYP2E1—Biological oxidations—GSTP1—bone cancer	0.00012	0.00138	CbGpPWpGaD
Zafirlukast—Vomiting—Methotrexate—bone cancer	0.00012	0.0023	CcSEcCtD
Zafirlukast—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	0.00012	0.00137	CbGpPWpGaD
Zafirlukast—Rash—Methotrexate—bone cancer	0.000119	0.00228	CcSEcCtD
Zafirlukast—Dermatitis—Methotrexate—bone cancer	0.000119	0.00228	CcSEcCtD
Zafirlukast—CYP2E1—Metapathway biotransformation—GSTP1—bone cancer	0.000118	0.00136	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—ATF1—bone cancer	0.000118	0.00136	CbGpPWpGaD
Zafirlukast—Headache—Methotrexate—bone cancer	0.000118	0.00227	CcSEcCtD
Zafirlukast—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000118	0.00135	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—NDUFA12—bone cancer	0.000117	0.00135	CbGpPWpGaD
Zafirlukast—Asthenia—Doxorubicin—bone cancer	0.000117	0.00225	CcSEcCtD
Zafirlukast—Dizziness—Epirubicin—bone cancer	0.000117	0.00224	CcSEcCtD
Zafirlukast—Pruritus—Doxorubicin—bone cancer	0.000116	0.00222	CcSEcCtD
Zafirlukast—CYSLTR2—Signaling Pathways—IL3—bone cancer	0.000115	0.00132	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—NDUFA12—bone cancer	0.000113	0.00129	CbGpPWpGaD
Zafirlukast—Vomiting—Epirubicin—bone cancer	0.000112	0.00215	CcSEcCtD
Zafirlukast—Nausea—Methotrexate—bone cancer	0.000112	0.00215	CcSEcCtD
Zafirlukast—Diarrhoea—Doxorubicin—bone cancer	0.000112	0.00214	CcSEcCtD
Zafirlukast—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000111	0.00128	CbGpPWpGaD
Zafirlukast—Rash—Epirubicin—bone cancer	0.000111	0.00214	CcSEcCtD
Zafirlukast—Dermatitis—Epirubicin—bone cancer	0.000111	0.00213	CcSEcCtD
Zafirlukast—Headache—Epirubicin—bone cancer	0.000111	0.00212	CcSEcCtD
Zafirlukast—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.000108	0.00124	CbGpPWpGaD
Zafirlukast—Dizziness—Doxorubicin—bone cancer	0.000108	0.00207	CcSEcCtD
Zafirlukast—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000107	0.00123	CbGpPWpGaD
Zafirlukast—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	0.000107	0.00123	CbGpPWpGaD
Zafirlukast—Nausea—Epirubicin—bone cancer	0.000105	0.00201	CcSEcCtD
Zafirlukast—CYP2C8—Biological oxidations—GSTP1—bone cancer	0.000104	0.00119	CbGpPWpGaD
Zafirlukast—Vomiting—Doxorubicin—bone cancer	0.000104	0.00199	CcSEcCtD
Zafirlukast—Rash—Doxorubicin—bone cancer	0.000103	0.00198	CcSEcCtD
Zafirlukast—Dermatitis—Doxorubicin—bone cancer	0.000103	0.00197	CcSEcCtD
Zafirlukast—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	0.000102	0.00117	CbGpPWpGaD
Zafirlukast—Headache—Doxorubicin—bone cancer	0.000102	0.00196	CcSEcCtD
Zafirlukast—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000101	0.00115	CbGpPWpGaD
Zafirlukast—CYP2D6—Biological oxidations—CYP3A4—bone cancer	9.97e-05	0.00114	CbGpPWpGaD
Zafirlukast—CYP2C9—Biological oxidations—CYP3A4—bone cancer	9.88e-05	0.00113	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—TGFBR2—bone cancer	9.87e-05	0.00113	CbGpPWpGaD
Zafirlukast—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	9.83e-05	0.00113	CbGpPWpGaD
Zafirlukast—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	9.75e-05	0.00112	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—NT5C3A—bone cancer	9.72e-05	0.00111	CbGpPWpGaD
Zafirlukast—Nausea—Doxorubicin—bone cancer	9.7e-05	0.00186	CcSEcCtD
Zafirlukast—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	9.69e-05	0.00111	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—SMO—bone cancer	9.65e-05	0.00111	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—NT5C3A—bone cancer	9.34e-05	0.00107	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—IGF1R—bone cancer	9.29e-05	0.00107	CbGpPWpGaD
Zafirlukast—CYP2C19—Biological oxidations—GSTP1—bone cancer	9.27e-05	0.00106	CbGpPWpGaD
Zafirlukast—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	9.14e-05	0.00105	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—GNA11—bone cancer	8.82e-05	0.00101	CbGpPWpGaD
Zafirlukast—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	8.6e-05	0.000987	CbGpPWpGaD
Zafirlukast—CYP2D6—Biological oxidations—GSTP1—bone cancer	8.53e-05	0.000978	CbGpPWpGaD
Zafirlukast—CYP2C9—Biological oxidations—GSTP1—bone cancer	8.45e-05	0.00097	CbGpPWpGaD
Zafirlukast—CYP1A2—Biological oxidations—CYP3A4—bone cancer	8.44e-05	0.000969	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—NDUFA12—bone cancer	8.42e-05	0.000966	CbGpPWpGaD
Zafirlukast—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	8.41e-05	0.000965	CbGpPWpGaD
Zafirlukast—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	8.34e-05	0.000956	CbGpPWpGaD
Zafirlukast—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	8.33e-05	0.000955	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—ATF1—bone cancer	8.2e-05	0.000941	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—IL3—bone cancer	8e-05	0.000918	CbGpPWpGaD
Zafirlukast—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	7.62e-05	0.000874	CbGpPWpGaD
Zafirlukast—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	7.62e-05	0.000874	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—NDUFA12—bone cancer	7.28e-05	0.000835	CbGpPWpGaD
Zafirlukast—CYP1A2—Biological oxidations—GSTP1—bone cancer	7.22e-05	0.000829	CbGpPWpGaD
Zafirlukast—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	7.12e-05	0.000817	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—NT5C3A—bone cancer	6.98e-05	0.0008	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—TGFBR2—bone cancer	6.84e-05	0.000785	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—KIT—bone cancer	6.73e-05	0.000773	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—NDUFA12—bone cancer	6.5e-05	0.000745	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—IGF1R—bone cancer	6.44e-05	0.000738	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—BRAF—bone cancer	6.33e-05	0.000726	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling by GPCR—EGFR—bone cancer	6.14e-05	0.000704	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—NT5C3A—bone cancer	6.03e-05	0.000692	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—NDUFA12—bone cancer	5.98e-05	0.000685	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—NDUFA12—bone cancer	5.92e-05	0.00068	CbGpPWpGaD
Zafirlukast—CYP3A4—Biological oxidations—GSTP1—bone cancer	5.57e-05	0.000639	CbGpPWpGaD
Zafirlukast—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	5.5e-05	0.000631	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—NT5C3A—bone cancer	5.38e-05	0.000618	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—MDM2—bone cancer	5.3e-05	0.000608	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—NDUFA12—bone cancer	5.06e-05	0.000581	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—NT5C3A—bone cancer	4.95e-05	0.000568	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—NT5C3A—bone cancer	4.91e-05	0.000563	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—KIT—bone cancer	4.67e-05	0.000536	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—JUN—bone cancer	4.61e-05	0.000529	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—MMP9—bone cancer	4.49e-05	0.000515	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—BRAF—bone cancer	4.39e-05	0.000503	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—ENO2—bone cancer	4.26e-05	0.000488	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling by GPCR—EGFR—bone cancer	4.25e-05	0.000488	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—NT5C3A—bone cancer	4.19e-05	0.000481	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—ENO2—bone cancer	4.09e-05	0.000469	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—DHFR—bone cancer	3.95e-05	0.000453	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—NDUFA12—bone cancer	3.91e-05	0.000448	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—DHFR—bone cancer	3.79e-05	0.000435	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—GNA11—bone cancer	3.69e-05	0.000423	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—MDM2—bone cancer	3.68e-05	0.000422	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—EGFR—bone cancer	3.62e-05	0.000416	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—GNA11—bone cancer	3.55e-05	0.000407	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—CYP3A4—bone cancer	3.35e-05	0.000384	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—NT5C3A—bone cancer	3.24e-05	0.000371	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—CYP3A4—bone cancer	3.21e-05	0.000369	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.2e-05	0.000367	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—JUN—bone cancer	3.2e-05	0.000367	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—MMP9—bone cancer	3.11e-05	0.000357	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—ENO2—bone cancer	3.06e-05	0.000351	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—TP53—bone cancer	3.04e-05	0.000349	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—GSTP1—bone cancer	2.86e-05	0.000328	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—DHFR—bone cancer	2.84e-05	0.000325	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—GSTP1—bone cancer	2.75e-05	0.000315	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—GNA11—bone cancer	2.65e-05	0.000304	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—ENO2—bone cancer	2.64e-05	0.000303	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—EGFR—bone cancer	2.51e-05	0.000288	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—DHFR—bone cancer	2.45e-05	0.000281	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—CYP3A4—bone cancer	2.4e-05	0.000276	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—ENO2—bone cancer	2.36e-05	0.000271	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—GNA11—bone cancer	2.29e-05	0.000263	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—DHFR—bone cancer	2.19e-05	0.000251	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—ENO2—bone cancer	2.17e-05	0.000249	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—ENO2—bone cancer	2.15e-05	0.000247	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—TP53—bone cancer	2.11e-05	0.000242	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—CYP3A4—bone cancer	2.08e-05	0.000238	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.07e-05	0.000237	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—GSTP1—bone cancer	2.05e-05	0.000236	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—GNA11—bone cancer	2.04e-05	0.000235	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—DHFR—bone cancer	2.01e-05	0.000231	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—DHFR—bone cancer	1.99e-05	0.000229	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—GNA11—bone cancer	1.88e-05	0.000216	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—GNA11—bone cancer	1.86e-05	0.000214	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—CYP3A4—bone cancer	1.85e-05	0.000213	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.84e-05	0.000212	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—ENO2—bone cancer	1.84e-05	0.000211	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—GSTP1—bone cancer	1.78e-05	0.000204	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—CYP3A4—bone cancer	1.7e-05	0.000196	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—DHFR—bone cancer	1.7e-05	0.000196	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—CYP3A4—bone cancer	1.69e-05	0.000194	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.68e-05	0.000193	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—GNA11—bone cancer	1.59e-05	0.000183	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—GSTP1—bone cancer	1.59e-05	0.000182	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—PTGS2—bone cancer	1.48e-05	0.00017	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—GSTP1—bone cancer	1.46e-05	0.000167	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—GSTP1—bone cancer	1.45e-05	0.000166	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—CYP3A4—bone cancer	1.44e-05	0.000166	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.44e-05	0.000165	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—PTGS2—bone cancer	1.42e-05	0.000163	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—ENO2—bone cancer	1.42e-05	0.000163	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—DHFR—bone cancer	1.32e-05	0.000151	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—GSTP1—bone cancer	1.24e-05	0.000142	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—GNA11—bone cancer	1.23e-05	0.000141	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—PTGS2—bone cancer	1.06e-05	0.000122	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—GSTP1—bone cancer	9.53e-06	0.000109	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—PTGS2—bone cancer	9.2e-06	0.000106	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—PTGS2—bone cancer	8.21e-06	9.42e-05	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—PTGS2—bone cancer	7.55e-06	8.67e-05	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—PTGS2—bone cancer	7.49e-06	8.59e-05	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—PTGS2—bone cancer	6.4e-06	7.34e-05	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—PTGS2—bone cancer	4.94e-06	5.67e-05	CbGpPWpGaD
